Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Trial of MLN0264 in Previously Treated Asian Patients With Advanced Gastrointestinal (GI) Carcinoma (Phase 1) or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma (Phase 2) Expressing Guanylyl Cyclase C (GCC)

NCT02391038 is registered in ClinicalTrials.gov with Millennium Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02391038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02391038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Trial of MLN0264 in Previously Treated Asian Patients With Advanced Gastrointestinal (GI) Carcinoma (Phase 1) or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma (Phase 2) Expressing Guanylyl Cyclase C (GCC)
Lead sponsor
Millennium Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
December 31, 2014
Completion date
October 31, 2015
Enrollment
12 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastrointestinal carcinoma, gastroesophageal junction adenocarcinoma, metastatic gastric adenocarcinoma, metastatic gastroesophageal junction adenocarcinoma, recurrent gastric adenocarcinoma, recurrent gastroesophageal junction adenocarcinoma, recurrent gastrointestinal carcinoma